Hysteroscopy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Hysteroscopy is the direct visual examination of the uterine cavity using a hysteroscope — a thin, rigid or flexible telescope with a fibre-optic light source and lens system, 2.9–8 mm in outer diameter, inserted through the vagina and cervix into the uterine cavity without an external incision. It is simultaneously diagnostic and operative, allowing visualisation of the entire endometrial cavity including the tubal ostia and guided tissue sampling. Hysteroscopy is classified as diagnostic (small 2.9–3.5 mm mini-hysteroscope used in an outpatient setting) or operative (larger 5–9 mm resectoscope used in theatre for therapeutic intervention). Distension media — normal saline (for bipolar electrosurgery) or glycine/sorbitol (for monopolar) — fills the cavity to create a working space. Hysteroscopy is performed by gynaecologists and is the gold standard investigation for intracavitary pathology — superior to ultrasound, saline infusion sonography (SIS), and MRI for detecting intrauterine adhesions, polyps, and submucosal fibroids. The 'see and treat' concept — performing diagnostic and operative hysteroscopy in a single outpatient visit — reduces waiting times and the number of procedures patients undergo.

This treatment represents an important component of modern medical management, supported by clinical evidence from multiple randomised controlled trials and systematic reviews. Treatment protocols are continually refined based on emerging evidence to optimise patient outcomes while minimising treatment burden.

Patient suitability is assessed through a structured multidisciplinary evaluation incorporating clinical history, physical examination findings, and results of relevant investigations. Treatment planning considers the full clinical context including disease characteristics, patient comorbidities, functional status, and individual treatment goals to ensure the most appropriate therapeutic approach is selected for each patient.

Hysteroscopy is indicated for the investigation and management of a wide range of uterine conditions. Abnormal uterine bleeding — the most common indication — includes heavy menstrual bleeding (menorrhagia), irregular bleeding, intermenstrual bleeding, post-coital bleeding, and post-menopausal bleeding. Post-menopausal bleeding with endometrial thickness over 4 mm on ultrasound requires urgent hysteroscopy and biopsy to exclude endometrial carcinoma or hyperplasia. Infertility investigations: hysteroscopy is indicated when HSG (hysterosalpingogram) or saline sonography suggests intracavitary pathology, or in unexplained infertility before IVF cycles — polyps and submucosal fibroids impair implantation and are corrected hysteroscopically. Recurrent pregnancy loss: intrauterine adhesions (Asherman syndrome), uterine septum, or submucous fibroids may cause recurrent miscarriage and are diagnosed and treated hysteroscopically. Retained products of conception or lost intrauterine devices (IUDs) requiring removal under direct vision. Endometrial biopsy (Pipelle or hysteroscopy-directed) for investigation of abnormal endometrial thickening or suspected malignancy. Hysteroscopic sterilisation (Essure coil placement) — a permanent contraception method performed without general anaesthesia, now less commonly performed following safety concerns in some regulatory jurisdictions.

For outpatient (office) hysteroscopy, the patient lies in the lithotomy position. A speculum is inserted to visualise the cervix. Topical anaesthetic (EMLA cream or paracervical block with lidocaine) is applied or injected 5 minutes before scope insertion. A mini-hysteroscope (2.9–3.5 mm outer diameter) in a no-touch technique (avoiding speculum and tenaculum where possible) is inserted vaginally into the cervical os and advanced with normal saline distension into the uterine cavity under continuous visualisation — the vaginoscopic approach. The cavity is systematically examined: anterior and posterior walls, fundus, both cornua, and tubal ostia are documented with video recording and photographic stills. Biopsies are taken with 5F cup forceps through the working channel. For operative hysteroscopy in theatre under general or regional anaesthesia, a resectoscope (7–9 mm) is used. After cervical dilation (Hegar dilators to 9–10 mm), the resectoscope is introduced. A bipolar electrode loop is used for transcervical resection of submucous fibroids (TCRM), endometrium (TCRE for endometrial ablation), and uterine septa. Polyps are excised with scissors or a bipolar loop. Intrauterine adhesions (synechiae) are divided with scissors under direct vision with laparoscopic surveillance if extensive. Distension media fluid balance is meticulously monitored throughout to prevent hyperabsorption and hyponatraemia — especially critical in monopolar procedures.

Hysteroscopy provides direct visualisation of the uterine cavity — no other investigation matches its accuracy for intracavitary pathology. Sensitivity and specificity for polyps exceed 90% and 95% respectively; for submucosal fibroids sensitivity is 90%+; for Asherman syndrome, hysteroscopy is the only definitive diagnostic and therapeutic modality. Hysteroscopic polypectomy resolves menorrhagia in over 80% of women with symptomatic polyps, avoiding hysterectomy in many cases. Transcervical resection of submucous fibroids (TCRM) controls fibroid-related heavy bleeding in 70–80% at 12 months. Endometrial ablation by TCRE eliminates or significantly reduces periods in 85–95% of suitable patients without hysterectomy. Hysteroscopic adhesiolysis in Asherman syndrome restores menstrual function in 80% and improves subsequent pregnancy rates by 50–60%. The 'see and treat' approach in outpatient hysteroscopy eliminates the need for a separate theatre session. In India, outpatient hysteroscopy costs approximately INR 8,000–20,000 (USD 100–240), compared to USD 2,000–5,000 in the USA. Operative hysteroscopy avoids the risks of laparotomy (open abdominal surgery) and hospital stays associated with traditional approaches.

Hysteroscopy is a very safe procedure with an overall complication rate of under 2%. Uterine perforation — the most significant complication — occurs in approximately 0.5–1% of diagnostic and up to 2% of operative procedures. Minor perforations without bleeding or organ injury are managed conservatively with observation; large perforations with suspected bowel or vessel injury require immediate laparoscopy or laparotomy. Cervical trauma from tenaculum or Hegar dilation causes minor bleeding in under 5%. Infection (endometritis, salpingitis) is rare (under 1%) and is treated with antibiotics; antibiotic prophylaxis is not routinely recommended for straightforward hysteroscopy. Fluid overload from distension media absorption can cause hyponatraemia, pulmonary oedema, and cerebral oedema — particularly with hypotonic monopolar media (glycine) in prolonged procedures; fluid balance monitoring and deficit limits (750–1,000 mL monopolar, 2,500 mL bipolar) are mandatory. Excessive haemorrhage during or after operative hysteroscopy may require vasopressin injection, balloon tamponade, or UAE. Uterine synechiae (adhesion) formation after intrauterine surgery (TCRE, polypectomy) can be minimised with post-operative oestrogen therapy and follow-up surveillance hysteroscopy.

After outpatient diagnostic hysteroscopy, mild uterine cramping and light vaginal spotting resolve within 24–48 hours. Analgesia with ibuprofen or paracetamol controls cramping. Patients can drive and resume normal activities the same day if no sedation was administered. After general anaesthesia for operative hysteroscopy, standard post-anaesthetic recovery of 1–2 hours is required before discharge. Moderate cramping and heavier vaginal bleeding lasting 3–10 days are expected after therapeutic procedures. Sanitary pads (not tampons) are used during any vaginal bleeding. Sexual intercourse and swimming are avoided for 1–2 weeks after operative procedures. Return to work is typically 1–2 days after outpatient hysteroscopy and 3–7 days after general anaesthesia. Biopsy results return within 5–10 working days. For Asherman syndrome adhesiolysis, post-operative oestrogen therapy (oral oestradiol 2–4 mg for 6 weeks) promotes endometrial regrowth and reduces re-adhesion formation. A check hysteroscopy at 6–8 weeks after adhesiolysis confirms complete division. After endometrial ablation, lighter periods are expected within 2–3 menstrual cycles; amenorrhoea (no periods) is achieved in 30–40%. If fertility preservation was the indication, the next menstrual cycle typically returns to normal 3–4 weeks post-procedure.